The Pleural Diseases Therapeutics Market covers pharmaceutical therapies (chemotherapy, immunotherapy, antibiotics, analgesics), surgical procedures (VATS, pleurodesis, thoracentesis), and medical devices (pleural catheters, drainage systems) for the treatment of malignant and non-malignant pleural conditions.
Market scope covers all commercially available products and services categorized by treatment (Treatment, Chemotherapy, Drug Class, Bullectomy, Video-Assisted Thoracoscopic Surgery, PleurX Catheter, Pleurodesis Therapy, Radiation Therapy, Thoracentesis, Thoracostomy), route of administration (Route Of Administration, Injectable, Oral, Intrapleural), technology (Technology, Conventional Therapies, Targeted Therapies), disease indication (Disease Indication, Malignant Pleural Diseases, Non Malignant Pleural Diseases), end users (End Users, Hospitals, Specialty Clinics, Others), distribution channel (Distribution Channel, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). Revenue coverage spans the 2026 to 2036 forecast period.
The scope does not include general pulmonology products not indicated for pleural diseases, lung cancer treatments without pleural involvement, or respiratory diagnostic equipment sold separately.
The Pleural Diseases Therapeutics Market is growing as treatment options expand for malignant and non-malignant pleural conditions. Chemotherapy holds 58.2% of the treatment segment, with drug classes (antibiotics, antifungals, corticosteroids, analgesics, NSAIDs), surgical procedures, and device-based interventions contributing the treatment mix. Injectable administration leads at 49.0%, reflecting the intravenous and intrapleural delivery requirements of chemotherapy and biologic agents.
Conventional therapies account for 52.0% of the technology segment, with targeted biologics and immuno-oncology therapies representing the growth segment. Malignant pleural diseases hold 61.0%, with pleurisy, pneumothorax, and other non-malignant conditions contributing additional treatment demand. Hospitals represent 64.9% of end-user demand.
Hospital pharmacies hold 44.5% of distribution, with retail and online pharmacies serving outpatient maintenance therapy prescriptions. The market is shaped by the multidisciplinary nature of pleural disease management, requiring coordination across pulmonology, oncology, thoracic surgery, and interventional radiology departments.
The Pleural Diseases Therapeutics Market is organized across 6 segmentation dimensions: Treatment, Route Of Administration, Technology, Disease Indication, End Users, Distribution Channel.
In 2026, Chemotherapy is expected to account for 58.2% of the Treatment segment. Key sub-categories include Systemic Chemotherapy, Combination Chemotherapy.
Chemotherapy holds 58.2% of the segment, contributing to segment diversity.
In 2026, Conventional Therapies is expected to account for 52.0% of the Technology segment. Key sub-categories include Pharmacological Therapy, Surgical Procedures.
Conventional Therapies holds 52.0% of the segment, contributing to segment diversity.
The Pleural Diseases Therapeutics Market is shaped by clinical demand, technology development, regulatory frameworks, and access dynamics. Growth reflects the balance between demand drivers and adoption constraints.
Mesothelioma treatment combines systemic chemotherapy (pemetrexed/cisplatin), surgical debulking, and radiation therapy. Checkpoint inhibitor approvals (nivolumab/ipilimumab) have expanded the treatment toolkit and created a high-value biologic therapy segment.
Malignant pleural effusion requires repeated drainage procedures, pleurodesis, or indwelling pleural catheter placement. These procedural interventions create recurring device and consumable demand at hospitals and ambulatory surgical centers.
Checkpoint inhibitor combinations approved for mesothelioma first-line treatment are shifting prescribing patterns from chemotherapy-only regimens toward immunotherapy combinations. This creates higher per-patient treatment costs and shifts revenue toward biologic products.
Improved pleural biopsy techniques, biomarker testing, and imaging advances are enabling earlier and more accurate diagnosis of malignant pleural conditions. Earlier diagnosis creates opportunities for curative-intent treatment and expands the treated patient population.
.webp "Top Country Growth Comparison Pleural Diseases Therapeutics Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| USA | 6.4% |
| UK | 6.2% |
| Japan | 6.3% |
| EU | 6.3% |
| South Korea | 6.4% |
The global Pleural Diseases Therapeutics Market is projected to expand at a CAGR of 6.3% from 2026 to 2036. The analysis covers more than 30 countries.
The United States is projected to grow at 6.4% through 2036. The largest oncology pharmaceutical market and mesothelioma treatment infrastructure are the primary factors shaping demand.
The United Kingdom is projected to grow at 6.2% through 2036. NHS cancer treatment pathways and mesothelioma specialist centers are the primary factors shaping demand.
Japan is projected to grow at 6.3% through 2036. Advanced thoracic surgery infrastructure and aging population demographics are the primary factors shaping demand.
The European Union is projected to grow at 6.3% through 2036. Harmonized oncology treatment frameworks and clinical trial activity are the primary factors shaping demand.
South Korea is projected to grow at 6.4% through 2036. Oncology treatment investment and clinical research participation are the primary factors shaping demand.
AstraZeneca plc holds a leading position through its oncology pipeline and device portfolio. Bristol-Myers Squibb maintains a strong position through complementary capabilities.
Becton, Dickinson and Company, Roche Holding AG (Genentech), Rocket Medical plc compete on specialized capabilities and Geographic Footprint. These companies serve distinct market segments through targeted strategies.
Market entry requires investment in oncology pipeline, regulatory compliance, and distribution infrastructure. Established companies benefit from customer relationships and track records.
Key global companies leading the Pleural Diseases Therapeutics Market include:
| Company | Oncology Pipeline | Device Portfolio | Specialist Distribution | Geographic Footprint |
|---|---|---|---|---|
| AstraZeneca plc | High | High | Strong | Global |
| Bristol-Myers Squibb | High | High | Strong | Global |
| Becton, Dickinson and Company | High | High | Strong | Global |
| Roche Holding AG (Genentech) | Medium | High | Moderate | Regional |
| Rocket Medical plc | Medium | High | Moderate | Regional |
| Novocure | Medium | High | Moderate | Regional |
| Smiths Medical | Medium | Medium | Low | Regional |
| Veracyte, Inc. | Medium | Medium | Low | Regional |
| Medtronic | Medium | Medium | Low | Regional |
| BioInvent International | Medium | Medium | Low | Regional |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Pleural Diseases Therapeutics Market
Major Global Players:
Emerging Players/Startups
| Parameter | Details |
|---|---|
| Quantitative Units | USD 6.00 billion to USD 11.06 billion, at a CAGR of 6.3% |
| Market Definition | The Pleural Diseases Therapeutics Market covers pharmaceutical therapies (chemotherapy, immunotherapy, antibiotics, analgesics), surgical procedures (VATS, pleurodesis, thoracentesis), and medical devices (pleural catheters, drainage systems) for the treatment of malignant and non-malignant pleural conditions. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | USA, UK, Japan, EU, South Korea, Italy, South Korea, 30 plus countries |
| Key Companies Profiled | AstraZeneca plc, Bristol-Myers Squibb, Becton, Dickinson and Company, Roche Holding AG (Genentech), Rocket Medical plc, Novocure, Smiths Medical, Veracyte, Inc., Medtronic, BioInvent International |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom-up and top-down methodology starting with verified data, projecting adoption velocity across segments and regions. |
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.
What is the global market demand for Pleural Diseases Therapeutics in 2026?
In 2026, the global Pleural Diseases Therapeutics Market is expected to be worth USD 6.00 billion.
How big will the Pleural Diseases Therapeutics Market be in 2036?
By 2036, the Pleural Diseases Therapeutics Market is expected to be worth USD 11.06 billion.
How much is demand expected to grow between 2026 and 2036?
Between 2026 and 2036, demand is expected to grow at a CAGR of 6.3%.
Which Treatment segment is expected to lead in 2026?
Chemotherapy is expected to account for 58.2% of the Treatment segment in 2026.
What is driving demand in USA?
USA is projected to grow at 6.4% through 2036, supported by the largest oncology pharmaceutical market and mesothelioma treatment infrastructure.
What is driving demand in South Korea?
South Korea is projected to grow at 6.4% through 2036, supported by oncology treatment investment and clinical research participation.
What does this report mean by 'Pleural Diseases Therapeutics Market definition'?
The Pleural Diseases Therapeutics Market covers pharmaceutical therapies (chemotherapy, immunotherapy, antibiotics, analgesics), surgical procedures (VATS, pleurodesis, thoracentesis), and medical devices (pleural catheters, drainage systems) for the treatment of malignant and non-malignant pleural conditions.
How does FMI forecast and validate the data?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified data and cross-checking against industry production data, regulatory databases, and manufacturer disclosures.
What is the global market demand for Pleural Diseases Therapeutics in 2026?
In 2026, the global Pleural Diseases Therapeutics Market is expected to be worth USD 6.00 billion.
How big will the Pleural Diseases Therapeutics Market be in 2036?
By 2036, the Pleural Diseases Therapeutics Market is expected to be worth USD 11.06 billion.
How much is demand expected to grow between 2026 and 2036?
Between 2026 and 2036, demand is expected to grow at a CAGR of 6.3%.
Which Treatment segment is expected to lead in 2026?
Chemotherapy is expected to account for 58.2% of the Treatment segment in 2026.
What is driving demand in USA?
USA is projected to grow at 6.4% through 2036, supported by the largest oncology pharmaceutical market and mesothelioma treatment infrastructure.
What is driving demand in South Korea?
South Korea is projected to grow at 6.4% through 2036, supported by oncology treatment investment and clinical research participation.
What does this report mean by 'Pleural Diseases Therapeutics Market definition'?
The Pleural Diseases Therapeutics Market covers pharmaceutical therapies (chemotherapy, immunotherapy, antibiotics, analgesics), surgical procedures (VATS, pleurodesis, thoracentesis), and medical devices (pleural catheters, drainage systems) for the treatment of malignant and non-malignant pleural conditions.
How does FMI forecast and validate the data?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified data and cross-checking against industry production data, regulatory databases, and manufacturer disclosures.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Pleural Diseases Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
